BIOINVENT
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR:registered:, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug d... iscovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers. BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others. BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.
BIOINVENT
Social Links:
Industry:
Biotechnology Health Care Manufacturing Pharmaceutical Product Research
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.bioinvent.se
Total Employee:
11+
Status:
Active
Contact:
(462) 868-550_
Email Addresses:
[email protected]
Total Funding:
2 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Font Awesome Microsoft Exchange Online Office 365 Mail Google Maps JsDelivr
Similar Organizations
Actient Holdings
Actient is a private urology specialty therapeutics company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Berlin Chemie
Berlin Chemie is an international pharmaceutical research company specializing the development and distribution of new pharma products.
Bharat Serums and Vaccines
Bharat Serums and Vaccines develops biopharmaceutical products for patient health improvement.
Biosearch
Biosearch is a state-of-the-art testing laboratory company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Janssen
Janssen is the pharmaceutical arm of Johnson & Johnson.
Medinfar
Medinfar is a Portuguese pharmaceutical company.
MSD
MSD is an research-based healthcare company.
Smartfish AS
Smartfish is a Norwegian, research-based company.
The Stevanato Group
Stevanato Group S.p.A. manufactures packaging containers from glass tubing for the pharmaceutical industry worldwide.
Current Advisors List
Current Employees Featured
Stock Details
Newest Events participated
Participated in BioProcess International European Summit 2017
on 2017-04-25 as exhibitor
Participated in Viral Safety 2017
on 2017-04-25 as exhibitor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-18 | BioInvent Appoints Experienced Industry Leader Marie Moores as Chief Operating Officer |
Official Site Inspections
http://www.bioinvent.se
- Host name: ec2-52-17-142-199.eu-west-1.compute.amazonaws.com
- IP address: 52.17.142.199
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "BioInvent"
About Us | BioInvent
BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology and antibody biology, BioInvent generates innovative immuno-oncology drug …See details»
Startsida | BioInvent
BioInvent är ett bolag som identifierar och utvecklar antikroppar för cancerbehandling. Baserat på djup kunskap inom immunologi, cancerbiologi och antikroppsbiologi, genererar BioInvent …See details»
Homepage | BioInvent
BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the pharmaceutical landscape. Partnerships within the big …See details»
Management - BioInvent
Andres joins BioInvent from a position as Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/ Pierre Fabre. Born 1956. Shareholding: …See details»
Bioinvent - Wikipedia
BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generatingnew drug candidates to fuel the Company’s own broad clinical development pipeline or for additional licensing and partnering. Currently, the company …See details»
Contact - BioInvent
BioInvent has a long history and a strong position in the generation and development of antibody drugs. The foundation of the company is expertise in immunology, cancer biology and …See details»
Bioinvent – Wikipedia
BioInvent International är ett svenskt forsknings-, läkemedels-och life science-företag med fokus på klinisk framtagning och utveckling av bland annat antikroppsläkemedel för immunterapi mot …See details»
Vår verksamhet | BioInvent
Se vår Pipeline av kliniska projekt. ... BioInvent Manufacturing är en affärsenhet inom Bioinvent International AB som erbjuder produktion till externa kunder. BioInvent har en lång erfarenhet …See details»
BioInvent International AB - A Company At Ideon
BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company focused on the development and development of antibody …See details»
Our History - BioInvent
BioInvent has a strong deal-making track record, and has ongoing collaborations with companies such as CASI, Merck, Daiichi and Mitsubishi Tanabe. Broad clinical pipeline BioInvent is …See details»
BioInvent strengthens the organisation with COO - BioStock
Feb 1, 2022 Swedish biotech BioInvent strengthened its pipeline of cancer treatments in 2021, entering the new year with four candidates in clinical phase, which is soon to be expanded …See details»
Bioinvent - Immunotechnology
Mar 11, 2021 BioInvent, founded in 1983, is working on developing drugs that use the body's own defense to treat a variety of cancerous diseases. The company also produces ordered …See details»
BioInvent announces 2024 strategic priorities and anticipated ...
Lund, Sweden – January 04, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in …See details»
Syfte | BioInvent
BioInvent har även forsknings- och utvecklingssamarbeten som baseras på bolagets teknologiplattform F.I.R.S.T™ och antikroppsbibliotek n-CoDeR ®. BioInvents …See details»
BioInvent anticipates strong influx of clinical data - BioStock
Oct 31, 2024 BioInvent has also reported significant progress during Q3 across multiple other clinical trials. Preliminary data from the phase IIa dose-expansion study of BI-1808 as a …See details»
Working at BioInvent
BioInvent Manufacturing, the contract manufacturing business unit of BioInvent International AB, has a proven track record for clients and partners since 1988. ... As a relatively small …See details»
BioInvent International Obtains ISO Certification on ESG, …
7 hours ago BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll …See details»
BioInvent uppnår ISO 26000-verifiering vilket belyser …
19 hours ago Lund, Sverige den 10 januari 2025 – BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), ett bioteknikföretag med fokus på upptäckt och utveckling av nya …See details»
Private equity firms among BioInvent International AB (publ)'s …
19 hours ago Institutional ownership in BioInvent International is 18%; If you want to know who really controls BioInvent International AB (publ) , then you'll have to look at the makeup of its …See details»
Investors | BioInvent
BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the …See details»